NEW YORK--(BUSINESS WIRE)--Despite a slight drop in the number of FDA drug approvals during first half 2015 (1H15), treatments for cancer remain an important component of pharmaceutical companies' R&D pipelines, according to a new Fitch Ratings report. One-third of all drugs approved by the FDA this year were cancer treatments, and positive early data on several drugs this summer indicate that the focus on these treatments will continue. "The clinical data presented at and since the America
| < Prev | Next > |
|---|
